SCHEMBL16790033

SCHEMBL16790033

CC1CN(C(=O)OC(C)(C)C)C(Cc2ccccc2)c2nnc(C(F)(F)F)n21

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.53
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 2/20 0.41
DPP4 P27487 6/20 0.41
DPP8 Q6V1X1 4/20 0.41
DPP9 Q86TI2 4/20 0.41
DPP7 Q9UHL4 1/20 0.41
KLK7 P49862 2/20 0.40
KLK5 Q9Y337 1/20 0.40
ABHD6 Q9BV23 1/20 0.40
DAGLA Q9Y4D2 1/20 0.40
CETP P11597 2/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
TACR1 P25103 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16790044 0.83 DPP4 (0.42) PARP1DPP4DPP8DPP9DPP7
SCHEMBL5935844 0.81 DPP4 (0.49) PARP1DPP4DPP8DPP9TACR1
SCHEMBL16790054 0.81 DPP4 (0.40) PARP1DPP4DPP8DPP9DPP7
SCHEMBL16789997 0.79 DPP4 (0.39) PARP1DPP4DPP8DPP9
SCHEMBL5637318 0.71 NR1H2 (0.59) PARP1NR1H2NR1H3DPP4KLK7
SCHEMBL273407 0.71 NR1H2 (0.59) PARP1NR1H2NR1H3DPP4KLK7
SCHEMBL271604 0.71 NR1H2 (0.59) PARP1NR1H2NR1H3DPP4KLK7
SCHEMBL16789995 0.71 DPP4 (0.41) PARP1DPP4DPP8DPP9CETP
SCHEMBL29997797 0.70 KLK7 (0.51) PARP1NR1H2NR1H3KLK7KLK5
SCHEMBL24723803 0.70 KLK7 (0.53) NR1H2NR1H3DPP4KLK7KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255106-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2016-02-09 US disclosed
US-20150166544-A1 PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) 2015-06-18 US disclosed
US-20150166544-A1 PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) 2015-06-18 US disclosed
EP-2881395-A1 PIPERAZINOTRIZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2015-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166544-A1 PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION PARP1, PARP11, PARP8 PARP1 1/4885NR1H2 1785/4885NR1H3 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.